Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)

Update Il y a 4 ans
Reference: NCT00732940

Woman and Man

Extract

The purpose of this study is to test the safety and tolerability of repeated subcutaneous (SC) doses of belimumab in subjects with SLE.


Inclusion criteria

  • Systemic Lupus Erythematosus

Links